Breaking Blind: Antipsychotic Drug Efficacy May Be Overestimated
Only 4 of 188 antipsychotic trials assessed blinding, and in all 4 cases, the blind was broken, potentially leading to an overestimation of the drug effect.
Cancer Risk Higher for Those on Clozapine
The antipsychotic clozapine, considered the âgold-standardâ treatment for psychosis, was found to increase the risk of blood and lymph system cancers.
Reduction/Discontinuation of Antipsychotics Produces Higher Long-Term Recovery
A study published today in the American Medical Association's journal JAMA Psychiatry reports that patients whose antipsychotic treatment was reduced or discontinued (DR) experienced a recovery...
Case Studies Reveal Patient Empowerment Through Tapering Antipsychotics
A new study shows how different patients respond to tapering antipsychotic medication under expert guidance, highlighting personal empowerment and the complexities of withdrawal.
In Chronic Patients, Antipsychotics Have Limited Efficacy in Reducing Symptoms
A large review and meta-analysis of 167 studies across 60 years dissects placebo-controlled randomized controlled trials of antipsychotic drugs.
FDA Warns About New Impulse-Control Problems Associated With Abilify
Yesterday, the US Food and Drug Administration (FDA) released a warning that the antipsychotic drug aripiprazole or Abilify is associated with compulsive and uncontrollable...
Wunderink: Antipsychotics Can Be Tapered Safely Without Increasing Relapse Risk
Tapering antipsychotics slowly and with supported decision-making may improve care for patients with psychosis.
Anticholinergic Drugs Increase Risk of Cognitive Decline
A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
Study Explores Cognitive Effects of Antipsychotics
Reduced usage of antipsychotics in first-episode psychosis was associated with improved executive functioning.
Keys to Successful Discontinuation of Antipsychotic Medication
Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.
New Study: The Clinical High Risk for Psychosis (CHR-P) Model Is Flawed
The CHR-P model focuses on âattenuated psychosisâ to predict âtransitionâ to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.
Tapered Antipsychotic Withdrawal Mitigates Risk of Psychotic Symptoms
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.
Service-Users See Long-Term Antipsychotic Use as Compromising Recovery, Review Finds
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Manufacturer of Tardive Dyskinesia (TD) Drugs Finds TD Emotionally Devastating
âPatients expressed feeling unaccepted by society or uncomfortable in their own skin⌠A few indicated that they would rather be dead than have tardive dyskinesia.â
Acute Respiratory Failure More Likely in COPD Patients Prescribed Antipsychotics
Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.
Antipsychotics Associated with High Risk of Death in Children
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Antipsychotic-induced Sexual Dysfunction Underreported
Researchers found some antipsychotics to be worse than others for causing sexual dysfunction.
New Rating Tool for Tapering Antidepressants and Antipsychotics
Researchers developed a rating scale to better assess service usersâ experiences tapering antidepressant and/or antipsychotic medication.
Antipsychotic Augmentation Increases Risk of Death
A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.
Review Finds FDA Approval of Digital Antipsychotic Misguided
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
Inappropriate Use of Antipsychotics on Adults with Intellectual and Developmental Disabilities
One-third of adults with an intellectual or developmental disability are dispensed antipsychotics, despite having no existing psychiatric diagnosis.
Anticholinergic Medications Linked to Cognitive Impairment in Schizophrenia
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.
Sudden Antipsychotic WithdrawalâNot Low DoseâLeads to Relapse
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
Industry Corruption in Systematic Review for Injectable Antipsychotics
Researchers highlight how systematic reviews are compromised by pharmaceutical industry ties by exposing a study of injectable antipsychotics.
Antipsychotics for Childhood “Behavioral Problems” Skyrocket
Researchers from Columbia University and other New York institutions found a dramatically increasing use of antipsychotics to treat ADHD and other behavioral problems in...
